Animal health company Elanco (NYSE:ELAN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.9% year on year to $1.37 bill...
Animal health company Elanco (NYSE:ELAN) announced better-than-expected revenue in Q1 CY2026, with sales up 14.9% year on year to $1.37 billion. The company ...
Animal health company Elanco (NYSE:ELAN) will be reporting results this Wednesday before the bell. Here’s what investors should know. Elanco beat analysts’ r...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Elanco’s 26.6% return over the past six months has outpaced the S&P 500 by 23.6%, and its stock price has climbed to $23.47 per share. This was partly thanks...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
The United States Department of Agriculture (USDA) has officially greenlit a massive $100 million initiative dubbed the "Screwworm Challenge," aimed at neutralizing a resurgent biological threat that hasn't plagued the American mainland in over half a century. As of March 2, 2026, federal authorities and state governments, led by Texas,
Shares of animal health company Elanco (NYSE:ELAN)
jumped 8.2% in the morning session after the company reported fourth-quarter results that surpassed Wall Street's expectations, with investors focusing on strong current performance over a mixed outlook for 2026. For the quarter,
Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.29 billion at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $0.13 per share was 15.6% above analysts’ consensus estimates.
Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026, the company finds itself at a pivotal crossroads. While it continues to dominate the multi-billion dollar markets for companion animal medicines [...]
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New World Screwworm Grand Challenge." The federal initiative is designed to spur rapid innovation in the detection, containment, and
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
